Menu
Currency
GWAS Study

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.

O'Donnell PH, Trubetskoy V, Nurhussein-Patterson A et al.

32378051 PubMed ID
GWAS Study Type
147 Participants
86 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

OP
O'Donnell PH
TV
Trubetskoy V
NA
Nurhussein-Patterson A
HJ
Hall JP
NA
Nath A
HD
Huo D
FG
Fleming GF
IJ
Ingle JN
AV
Abramson VG
MP
Morrow PK
SA
Storniolo AM
FA
Forero A
VP
Van Poznak C
LM
Liu MC
CJ
Chang JC
MD
Merkel DE
PJ
Peppercorn JM
RH
Rugo HS
DE
Dees EC
HO
Hahn OM
HP
Hoffman PC
RG
Rosner GL
HR
Huang RS
RM
Ratain MJ
CN
Cox N
OO
Olopade OI
WA
Wolff AC
DM
Dolan ME
NR
Nanda R
Chapter II

Abstract

Summary of the research findings

Purpose: Capecitabine is important in breast cancer treatment but causes diarrhea and hand-foot syndrome (HFS), affecting adherence and quality of life. We sought to identify pharmacogenomic predictors of capecitabine toxicity using a novel monitoring tool.

147 European ancestry individuals

Chapter III

Study Statistics

Key metrics and study information

147
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.